ArticleAntonie van Leeuwenhoek2026
Mycobacterium cajalii sp. nov., a novel scotochromogenic rapid-growing nontuberculous mycobacterial species closely related to Mycobacterium servetii.
Article in Antonie van Leeuwenhoek, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Validation list no. 231: valid publication of new names and new combinations effectively published outside theInternational journal of systematic and evolutionary microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-tuberculous mycobacteria (NTM) represent an expanding group of environmental microorganisms with growing clinical significance, particularly among immunocompromised patients. In this study, we describe the isolation and comprehensive characterization of a novel Mycobacterium species, strain HUMS_1102779-3, recovered from a sputum sample of a patient undergoing diagnostic bronchoscopy for hilar lymphadenopathy. Initial identification attempts using MALDI-TOF MS and commercial DNA∙STRIP assays were inconclusive, prompting whole-genome sequencing for comprehensive genomic and phenotypic characterization. De novo genome assembly resulted in a 6.2 Mb draft genome with a GC content of 69.03 mol% and high completeness (98.4% conserved orthologues). Phylogenetic and genomic comparisons suggest close relationship to Mycobacterium servetii (ANI 94.52%, dDDH 63.5%), yet below the accepted species delineation thresholds (95% and 70%, respectively), thereby supporting its status as a distinct taxon within the Mycobacterium simiae complex. Phylogenomic reconstruction placed HUMS_1102779-3 within a monophyletic cluster neighboring M. servetii and Mycobacterium helveticum, but genetically divergent from them. The genome encoded 5833 coding sequences, including determinants associated with antimicrobial resistance (rbpA, rpoB-like variant, mtrA, efpA), as well as virulence-related genes typical of mycobacteria, such as components of the Type VII secretion system and iron-regulated factors (ideR, hbhA). No mobile genetic elements were detected. Phenotypically, the isolate is a fast-growing, scotochromogenic, acid-fast bacillus that exhibits notable dimorphism on 7H11 agar and produce rough yellow-orange colonies after 4-5 days at 35 °C. It differs from M. servetii by several biochemical traits (catalase negative, Tween 80 hydrolysis positive, tellurite reduction-positive) and distinct antimicrobial susceptibility patterns, notably higher MICs for linezolid and minocycline and lower for ciprofloxacin. Based on genomic, phylogenetic, and phenotypic evidence, we propose the designation Mycobacterium cajalii sp. nov.,. The type strain is HUMS_1102779-3 (= CECT 31296 = DSMZ 120455), with the genome deposited under genome assembly accession number ASM4580900v1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.